Company intelligence / Profile preview
Precision Virologics
St. Louis, Missouri, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Precision Virologics’ intranasal chimp-adenovirus COVID-19 vaccine, developed using a proprietary molecular engineering approach, demonstrated full protection and sterilizing immunity in mouse models. As of late 2020, the COVID-19 program was advancing into Phase 1 trials in the US; further updates on efficacy or late-stage results were not found.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineAdenoviral vector-based therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bharat BiotechWashington University School of Medicine in St. Louis
Beyond the preview
Go deeper on Precision Virologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precision Virologics.